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Abstract

Sexually transmitted infections (STI) such as Neisseria Gonorrhoeae and Chlamydia
Trachomatis pose a challenge to the healthcare system worldwide. Treating sexual partners is as
crucial to controlling the spread of these infections as treating index patients. However, because
of problems associated with stigma, reaching affected populations, and ensuring follow-up,
unique solutions are require to ensure partners receive treatment. One solution is Expedited
Partner Therapy (EPT). EPT refers to treating patients, and providing necessary medication for
both patient and partner. Current recommendations are for oral doses one gram of azithromycin
and 400 milligrams of cefixime. This literature review looked at thirteen studies, and aimed to
determine whether EPT is still superior to standard partner notification at reducing further
infection, and reinfection in adult Gonorrhea and Chlamydia (GC) patients in the US. Research
indicates that EPT remains a viable, cost-effective measure at controlling the spread of GC
infections. EPT appears to be the best available option despite use of second-line treatments in
resistance-prone infections. Additionally, there is a need for future, large-scale, US-based
randomized controlled trials to unequivocally show the continued effectiveness of EPT.

Keywords: Gonorrhea, Chlamydia, EPT, STI, Azithromycin, Cefixime, Gemifloxacin, Expedited
Partner Therapy, Sexually Transmitted Disease, Ceftriaxone, Partner Notification, Partner
Treatment
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Despite continuing public health efforts, sexually transmitted infections (STI) caused by
Neisseria Gonorrhoeae a nd Chlamydia Trachomatis continue to impose a significant healthcare
burden in the United States and beyond. One of the central problems with interventions aimed at
controlling the spread of these infections is how to treat a patient’s partners and sexual contacts.
Traditional methods employed in Emergency Departments, STI/Public Health, and primary care
clinics rely on the patient to relay their current infectious state to their partners and contacts.
Additionally, the onus is on the patient to encourage the partner or sexual contact to present for
treatment.
The current treatment regimen for N. Gonorrhoeae infection recommended by the
Centers for Disease Control and Prevention (CDC) is 250 milligrams (mg) ceftriaxone given
intramuscularly (IM), and azithromycin 1 gram (g) given orally as a single in-clinic treatment.
The CDC recommended treatment for lab-confirmed chlamydial infection without gonorrheal
co-infection is azithromycin 1g orally as a single, in-clinic dose. These current regimens are
first-line treatments in order to avoid rising resistance among both N. Gonorrhoeae and C.
Trachomatis strains in the United States.
Expedited Partner Therapy (EPT) is one method by which clinicians can attempt to treat
sexual contacts of infected gonorrheal and chlamydial (GC) patients without the contact needing
to present themselves for treatment. In most scenarios, patients are given packets containing
cefixime 400 mg oral tablets along with azithromycin 1g oral tablets to give to their partners.
The advantages of this treatment method are that it enables contacts who are unwilling or
hesitant to present themselves in clinic a way to receive treatment, and it allows patients a more
effective method of notifying partners of their infection and providing on the spot treatment.
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Statement of the Problem
The crucial drawback of EPT is found in the choice of antibiotics. As the recommended
first line treatment (ceftriaxone) is given in-clinic as an injection, EPT packets must contain a
second-line choice which must be available orally. In the US, that choice is currently cefixime.
The purpose of this study is to examine the body of literature surrounding cefixime, gonorrheal
and chlamydial (GC) infections, and EPT specifically to see whether the use of a second-line
drug treatment is still superior to following more traditional methods of partner notification and
clinic presentation.
It is important to note here that any time a treatment modality is used that explicitly
avoids evidence-based best practices, we can consider such a modality a form of harm reduction.
As such the choice may be between an inferior treatment, or no treatment at all. This literature
review will attempt to examine relevant studies to determine whether EPT remains the superior
choice compared to the potential for no treatment of GC infections in sexual partners. Some
studies are large, ecological surveys of GC epidemiology. Some are retrospective cohort studies,
and a few are randomized, controlled trials often conducted at the state or local public health
jurisdictional level.
This is a unique situation in infectious disease treatment where first-line treatment is not
possible due to the route of administration, and the second-line treatment has been shown to be
demonstrably inferior. Therefore, researchers and clinicians need to know: should we still be
providing cefixime to partners who can’t or won’t seek treatment on their own? Does the benefit
of treating potentially resistant strains of gonorrhea with cefixime outweigh the risks of
re-infection or treatment failure?
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Research Question
Is Expedited Partner Therapy using oral cefixime and azithromycin for treatment of GC
Infections still superior to standard partner notification among adult outpatients in the US in
reducing further infection and reinfection rates?
Research Methods
This project was performed as a literature review, primarily aimed at examining
randomized, controlled trials, retrospective studies, cohort studies and other observational
analyses. The primary databases which were searched were PubMed and Cochrane Database.
Primary parameters for the searches included peer-reviewed articles and studies conducted
within the last 20 years which discussed or studied the primary themes of this review:
Patient-Delivered Partner Therapy (a term often used interchangeably with EPT), use of oral
cefixime for GC infections, and the rise of antibiotic resistance in GC infections. Initial
parameters were set to include studies published within the last five years, however it was
determined that due to the relative paucity of research on EPT, several key studies from the early
2000’s should be included. This required us to broaden the search period to the last 20 years of
peer-reviewed research.
PubMed was primarily searched using MeSH headings. Seven relevant MeSH headings
were identified: “Cefixime”, “Ceftriaxone”, “Azithromycin”, “Gonorrhea”, “Chlamydia”,
“Sexually Transmitted Diseases, Bacterial”, and “Contact Tracing.” Various MeSH subheadings
were then included under each top-level subject heading. Additional general PubMed search
terms identified were “Partner Notification”, “Expedited Partner Therapy”, and
“Patient-Delivered Partner Therapy”. Cochrane Database was searched using the MeSH
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headings as noted above, entered as primary search terms (in addition to the general PubMed
terms). A total of thirteen studies were identified using the above search terms, with publication
dates ranging from 2005-2018. Seven were randomized, controlled clinical trials, five were
retrospective and cohort analyses, and one was a Cochrane Review statistical meta-analysis. This
was not a systematic review of EPT and ancillary literature, nor a comprehensive meta-analysis
(although one meta-analysis was reviewed), rather an update looking at the most current state of
EPT-related literature.
Expedited Partner Therapy vs. Standard Partner Notification
Performing large, randomized controlled trials of interventions such as EPT is difficult at
the best of times. As such, the study by Golden, et al. (2015) represents the most comprehensive
RCT to date looking at EPT use in the United States. The authors introduced EPT to county-level
public health jurisdictions across Washington State in a stepwise manner over the course of 6
months. They used GC infection rates and provider use of EPT as the primary outcomes. The
results showed significantly higher uptake of EPT use among providers in the study jurisdictions,
however the actual impact on infection rates was less clear after statistical analysis.
The statistical analysis showed significance when measuring the rates of EPT use (as
measured by the number of patients receiving EPT to take to their partners) which increased
from 18% to 34% across the population, with p<0.001 (Golden, et al., 2015). When looking at
the second primary outcome, positive gonorrheal test rates and gonorrheal incidence, the
confidence intervals for both reductions crossed one, with p=0.15 and 0.45 respectively. The
authors correctly surmised that there was no statistically convincing evidence that EPT uptake
significantly decreased these two metrics.
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Additional drawbacks of the study were noted by the authors. Certain communities were
excluded from the study (notably Seattle/King County) which already had robust EPT programs
and could not be “feasibly stopped and restarted [for the study].” (Golden, et al., 2015). The
authors devoted a large portion of their discussion to the potential lack of statistical power
(especially the potentially small number of participants for the size of the overlying population).
Another drawback noted by this literature review was the primary gonorrheal metrics being
measured through GC tests administered to women aged 14-25 presenting to local STI and
Planned Parenthood clinics. This conspicuous lack of male metrics may be due to the lack of
high-volume clinics catering specifically to men, but nevertheless puts the generalizability of
these results into question. This is especially true as the EPT interventions were not limited to
female patients.
As noted in the previous study, direct studies examining EPT head-to-head with standard
partner notification are relatively few in number. The study by Golden and Kerani, et al. (2005)
looked at a much smaller population than its 2015 follow-up. In this particular case, patients
presenting with laboratory-confirmed GC infections at one of two Seattle/King County public
STI clinics were randomized to one of two interventions: either a cefixime/azithromycin EPT
packet to give to their known sexual partners, or referrals for standard partner notification and
invites for contacts to present themselves for treatment.
Statistical results showed that EPT was associated with lower persistent or recurrent
gonorrheal infections than standard partner notification (p=0.01). Interestingly, recurrent or
persistent chlamydial i nfection rates were not lower among EPT participants with a p=0.17. The
relative risk associated with EPT was shown to be 0.75, meaning the EPT group had only 75%
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chance of experiencing recurrent or persistent infection as compared to the control of standard
partner notification. In this last case, results were noted by the authors to be statistically
significant with the 95% confidence interval including the noted value and not crossing one
(Golden, et al., 2005).
Despite these promising results, there were several drawbacks noted in this study.
Perhaps most importantly, this study was conducted in 2005, over 13 years ago. Typically, such
long intervals might lead one to preclude such studies on their face, however it was decided that
because this particular study was so clearly on point with our research question (and so few
studies were found that were) that it warranted inclusion. However, 2005 is not 2018 and
antibiotic resistance has changed significantly. In 2005, the CDC still recommended oral
cefixime as a first line treatment for gonorrhea. These results should be assessed with this
knowledge in mind.
Additionally, as far as the included population, this study notably excluded self-identified
men who have sex with men (MSM). The population included self-identified women and
heterosexual men, arguably missing a key population for intervention (Golden, et al., 2005). This
would therefore possibly impair the generalizability of this study to all adult populations in the
US. Additionally, the lack of strong evidence for chlamydial cure following EPT was not
thoroughly discussed, although the authors noted it was beyond the scope of this particular study.
In summary, this 2005 study might serve as a valuable blueprint for further studies into EPT,
especially the randomized controlled trials.
Although referencing older studies (as noted above) is often less than ideal, Kissinger, et
al.’s (2005) study represents the second such study evaluated for this literature review. In this
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randomized controlled trial, a public STI clinic in New Orleans, Louisiana enrolled male patients
presenting with confirmed C. trachomatis and N. gonorrhoeae infections. This trial was notable
for being a targeted, in-depth comparison of EPT at a single source where control of
interventions was directly at patient-level. Unlike the previous two EPT randomized, controlled
trials, the New Orleans study also tracked patient follow-up by quantifying how often the
patient’s contacts took the EPT medications. This is an important metric for any evaluation of
EPT results.
Statistical analysis showed several promising results, notably that the study was
significant for how often patients completed their randomized intervention. 69% of EPT patients
gave the medications directly to their partners versus 49% of the partner referral patients told
their contacts to get treated. For this particular result, statistics were encouraging with p<0.001.
Crucially, the evaluation of follow-up GC infection rates was lower for EPT patients (23%
positive for re-infection versus 42.7% for standard partner referral patients), and for this statistic,
again p<0.001. However, while the statistics were generally presented as favorable in showing
the significant impact of EPT against standard of care, no in-depth discussion of the statistical
methodology was included, raising concerns about reproducibility (Kissinger, et al., 2005).
Perhaps the most glaring drawback in this study’s relevance was its use of ciprofloxacin
for a period during 2003 (Kissinger, et al., 2005). Ciprofloxacin is no longer a recommended
treatment for GC infections as of 2018, as resistance is widespread. This makes it difficult to
generalize the study to today’s clinical environment where ciprofloxacin is no longer a viable
option. Additionally, the population was relatively small, enrolling only male patients at one STI
clinic in one city. Notably (and perhaps unintentionally), over 95% of participants were of
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African-American race, which has the potential to skew results and impair generalizability.
Nevertheless, this study is important because, like the previous trial reviewed, it provides
important blueprints for how to potentially reproduce such trials in the current clinical
environment.
Partner Notification Methods - Meta-Analysis
Our literature review revealed one systematic review of randomized, controlled clinical
trials directly discussing the effectiveness of EPT (Ferreira, et al., 2013). This Cochrane review
included eight trials covering EPT: Cameron et al. (2009), Golden et al. (2005), Kerani et al.
(2011), Kissinger et al. (2005), Kissinger et al. (2006), Nuwaha et al. (2001), Schillinger et al.
(2002) and Schwebke et al. (2010). The benefit of systematic reviews such as those found in the
Cochrane Database lies in the strength of their evidence. Hierarchically they offer the best
panoramic view of the strength of clinical evidence for or against a particular intervention. In this
case, EPT was shown to be superior to traditional partner referral but not superior to “enhanced
partner referral” which presumably included more robust interventions aimed at encouraging
partners to seek treatment. Ferreira, et al. (2013) noted that any effective EPT program should
therefore be sure to include these enhanced measures as the evidence clearly showed that each
was preferable to standard partner referral, but that the sum was greater than the two parts.
Statistically, this Cochrane review surveyed the 6 identified EPT-based randomized
controlled trials and noted that EPT was again superior to standard partner referral at preventing
reinfection (RR of 0.71 with a 95% confidence interval 0.56-0.89, which included the named
value and did not cross one) (Ferreira, et al., 2013).
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The drawback to this particular systematic review is the same that the previous studies
experienced: lack of timely relevance. None of these RCTs directly demonstrate the continued
superiority of EPT over standard partner referral in the current microbiological environment.
Cefixime has since been relegated to second-line therapy, and resistance to first line ceftriaxone
injectable therapy in North America is being reported in the literature (Lefebvre, B. et al., 2018
and Papp, J.R., et al., 2018). However, it is important to note that drawbacks can be seen as
positives depending on the perspective. In this particular case, EPT continues to be
recommended if standard patient referral is impossible or unlikely. Nevertheless, the landscape
of antibiotic resistance appears to be continually shifting. Therefore, this Cochrane review
highlights the need for additional RCTs to evaluate EPT with current microbiological trends.
Efficacy of Cefixime as Second-Line Treatment
In addition to RCTs evaluating EPT, there are many other studies indirectly related to our
research question that may be of benefit. In the case of Whittles, et al.’s (2017) study on cefixime
resistance in N. gonorrhoeae, we see a statistical argument that cefixime may not be as
ineffective as recently thought. This study was essentially a large retrospective cohort study
which was then applied to a complicated statistical model. Men who have sex with men (MSM)
gonorrheal infection data was gathered from 2008 to 2015 in England through the National
Health Service. This timeframe is important because it represents the beginning of the
ceftriaxone era in GC treatment.
Statistically, the authors of this study applied two concepts: mathematical modelling and
Bayesian inference (Whittles, et al., 2017). They detected a significant decrease in cefixime
resistance in England (under 1% as of 2014), however statistical significance of this finding was
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neither noted or discussed. Notably, they showed evidence that cefixime resistance has actually
diminished among common strains of N. gonorrhoeae. They argued the statistical model showed
that cefixime could be re-introduced to treat a minority of gonorrhea cases without causing a
second resistant epidemic. The central hypothesis of this study is that MSM in England were
previously a population heavily infected with the G1407 strain of gonorrhea, which was a prime
mediator of cefixime resistance (Whittles, et al., 2017). By introducing first-line
ceftriaxone/azithromycin dual therapy, the G1407 strain is declining, causing cefixime resistance
to decline with it.
A serious drawback of this study was highlighted in a review article by Unemo and
Althaus (2018) in which they argued that cefixime was removed from treatment in favor of
ceftriaxone but cefixime resistance remains high. As such, this hypothesis may be less durable
outside of the specific English MSM population on which it was based. Because of this, and the
prospective and hypothetical outlook of using a mathematical model make this study less reliable
in showing the current utility of oral cefixime for use in EPT. Drawbacks in patient population
and setting (MSM and England, respectively) also limit the generalizability of these findings to
the adult population in the United States.
Whereas the previous study attempted to feed gonorrhea treatment data into a
mathematical and predictive model, Town, et al. (2018) conducted a retrospective study aimed at
evaluating the effectiveness of previously used antibiotics on current strains of N. gonorrhoeae
in England. They evaluated susceptibility to three drugs: penicillin, ciprofloxacin and cefixime.
By using clinical isolates from STI testing across England, they performed susceptibility testing
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to see which drugs remained effective. In this case, the 95% susceptibility threshold for
acceptable antibiotic use by the World Health Organization was used.
Results showed predictably that only cefixime approached the 95% threshold of
susceptibility. Because the samples were primarily stratified by sexual orientation (MSM vs.
heterosexual), the authors showed that cefixime was significantly more susceptible among
heterosexuals than among MSM (between 96-96% for heterosexuals, p<0.001 and 81-82% for
MSM, p =0.05) (Town, et al., 2018).
It should be noted that this was the first study which directly discussed the significance of
the 95% threshold for susceptibility. It detailed how the origins for this threshold were “obscure,
and originated at a time when there were more antimicrobials that met this criterion than are
currently available.” (Town, et al. 2018). This is important to note as it brings up the possibility
that we may be entering an era where 95% susceptibility may be unrealistic or even impossible
as susceptibilities decline. However, the authors recognize this avenue of research is as yet
untouched. This study again suffers from generalizability issues in that it focused exclusively on
the differences in three previously used drugs comparing their effectiveness between MSM and
heterosexual patients. Nevertheless, it does provide population-level data that cefixime use may
still be warranted in situations that demand EPT.
Alternatives to Oral Cefixime
According to the CDC, there are only two recommended treatment regimens for
uncomplicated GC infections: ceftriaxone IM with oral azithromycin, and as an alternative, oral
cefixime with oral azithromycin (the therapy being evaluated in this review) (CDC, 2016).
Additional alternative choices exist (although two are non-FDA approved as of January, 2019),
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and should be considered when looking at the efficacy of cefixime/azithromycin as the best
choice for EPT. To date, the best available evidence for oral alternatives are three antibiotics
available in oral form: gemifloxacin, zoliflodacin (ETX0914), and solithromycin (CEM-101). Of
these, only gemifloxacin is FDA-approved in the US, with zoliflodacin and solithromycin in
Phase II/III clinical trials as of 2019.
One study by Kirkcaldy, et al. (2014) looked at using either gentamicin IM plus oral
azithromycin or oral gemifloxacin plus oral azithromycin for treatment of gonorrhea. Because
EPT by definition requires oral treatment, the gemifloxacin regimen is of interest here.
Kirkcaldy’s study was a randomized, controlled trial including 200 participants in each arm
(gentamicin or gemifloxacin). In the case of the gemifloxacin, 99.5% cure rates were achieved
for gonorrheal infection.
Statistically, this study was not a comparative trial. The authors described it as
“establish[ing] efficacy data for 2 candidate regimes [gemifloxacin and gentamicin]” (Kirkcaldy,
et al., 2014). The research question focused on effective GC cure rates for the two treatments, as
such 95% confidence intervals did include the 99.5% cure rate described by the authors.
One notable detail described by the authors of the gemifloxacin/gentamicin study
regarded potential adverse effects. Current EPT using Cefixime is associated with relatively low
incidence of adverse effects (ex: California’s department of public health reported no instances
of reported adverse effects over 15 years of EPT use) (2016). However, Kirkcaldy, et al. (2014)
did note a 7.7% incidence of adverse effects among gemifloxacin patients, notably manifested as
vomiting and GI discomfort. This is important considering that EPT patients are by definition
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unmonitored and often anonymous. Additionally, an oral medication that causes vomiting might
be associated with lower cure rates due to low absorption.
It should be noted that this trial and other evidence pertaining to alternative oral GC
therapies all suffer from low power and small sample sizes. Kirkcaldy, et al. (2014) had 200
participants in each arm of the study. A similar study using the Phase II experimental
fluoroketide Zoliflodacin (ETX0914) in 2018 had 141 participants (Taylor, et al., 2018), and a
much smaller trial using the Phase III experimental macrolide Solithromycin (CEM-101) in 2013
enrolled only 41 patients. The CDC discusses these alternative therapies but notes that their
utility is lower because of the potential for GI side effects in the case of gemifloxacin. The CDC
also discusses the two novel antibiotics Zoliflodacin and Solithromycin as being of interest but
lacking strong enough evidence and their lack of FDA approval to date. (CDC, 2016).
Social and Economic Aspects of Expedited Partner Therapy
Although RCTs are important in properly gauging evidence for EPT’s effectiveness, post
hoc analyses of EPT acceptance is also crucial to success. Without high uptake by eligible
patients, an intervention such as EPT can quickly cross from acceptable harm reduction to
wasteful use of resources, especially if evidence shows better infection control could be achieved
using other methods. The only post hoc analysis of US EPT programs found in this literature
review was conducted by Vainya, et al. (2014) and evaluated the uptake and acceptance by index
patients infected with Chlamydia trachomatis in STI clinics in New York City. Presumably, the
EPT offered was either oral Azithromycin 1g or a combination of Cefixime 400 mg and
Azithromycin 1g (in the case of concomitant gonorrhea infection).
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Results showed that when adjusting for patients whose partners had already sought
treatment or were present at the time of index patient diagnosis, 69.4% of patients accepted EPT
from the provider. Notably, the most predictive values for accepting EPT were overt signs of
chlamydial infection in index patients and male healthcare providers offering EPT (Odds Ratio
1.32 and 1.30 respectively, with 95% confidence intervals including the named value and not
crossing one) (Vainya et al., 2014).
Although this study was retrospective in nature, and excluded MSM, it nevertheless has
high utility for the general study of EPT. It should be noted that any robust public health measure
(such as EPT) which costs time and money to implement, promote and maintain, can be shown
to have poor uptake by the targeted population despite the best of intentions. In the case of EPT,
where a second-line antibiotic is being offered in lieu of evidence-based first-line therapy, if
uptake is low then serious consideration should be given to whether EPT resources would be
better invested in other population-level initiatives. In the case of this study however, it shows
that 7 out of 10 eligible patients accepted EPT therapy. (Vainya, et al., 2014). It should be noted
however, that this study only looked at chlamydial infections, and while some patients
undoubtedly were experiencing gonorrheal coinfection, the generalizability of such results may
be of less utility with EPT looking at both gonorrheal and chlamydial infections.
At least one recent study has evaluated pregnant female patients and their acceptance of
EPT. Unger, et al.’s (2015) study evaluated EPT within the context of a larger HIV diagnosis
program at a women’s clinic in Kenya. Women being screened for STIs who had a bacterial
infection were then offered EPT in lieu of standard partner referral. This study was notable as the
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only study found in this literature review that included Trichomonas vaginalis infections by
including oral metronidazole in EPT packets if patients tested positive.
Statistically, this study had one notable measure that seems germane to the current
research question. In this case, patients were specifically interviewed pre- and post-EPT as to
whether fears of partner anger or abuse factored into whether the partner was ultimately treated
or not. In this small population, no statistical difference was noted between partners treated and
those not as to whether such fears impacted the index patient’s willingness to deliver EPT
(p>0.05 in all cases) (Unger, et al., 2015).
This element is important because not only is this study helpful in evaluating a patient
population notably absent in previous studies (pregnant females) but also in evaluating concerns
over intimate partner violence. In other words, because any intervention aimed at controlling GC
infection should not cause any harm, such results are promising. It should be noted that the
authors did not delve deeper into this area of study, and such results should not be viewed as
strong evidence for ruling out intimate violence concerns with EPT (Unger, et al., 2015). One of
the study’s main drawbacks is indeed the small sample size and the prospective nature of the data
(prospective cohort study). It nevertheless is helpful and encourages further study of this
important social impact of EPT.
Assessing an intervention’s cost is an often-overlooked aspect of that intervention’s
long-term viability and success. In perhaps the most interesting study evaluated in this literature
review, Gift, et al. (2011) looked at comparing the cost and cost-effectiveness of EPT versus
standard patient referral, using data from two previous studies already examined in this review
(Golden, et al., 2005 and Kissinger, et al., 2005). By evaluating the system cost and the

EXPEDITED PARTNER THERAPY

20

individual cost through direct dollar amounts and quality-adjusted life years (QALYs), this study
was able to show EPT to be associated with significant cost savings from a systems perspective,
however the cost to the individual may be higher based on the number of partners.
Statistically, the main drawback in reviewing this study was the lack of identifiable
significance markers. P-values or confidence intervals did not appear within the text or tables,
and percentages and numbers did not specify which tests were used to establish significance.
The authors describe using the monte carlo method to evaluate numerical results, and this
reviewer’s rudimentary understanding of the applications of the monte carlo method was not
enough to truly evaluate the strength of the evidence (as such its significance may be clear, but
beyond our understanding) (Gift, et al., 2011). Nevertheless, the numbers and results presented,
if significant, represent good news for EPT. By demonstrating cost savings, larger health systems
with commercial payers who may not be using EPT (unlike the often-studied public STI clinics)
may be willing to consider the practice.
Unfortunately, the data used from Kissinger et al. (2005) and Golden, et al. (2005) may
not be recent enough to demonstrate generalizability to today’s healthcare market. The major
changes brought forth from the 2012 implementation of the Affordable Care Act (ACA) may
have altered the landscape enough to make this data totally irrelevant. It should still be seen as a
valuable addition to this literature review given its blueprint for a direct assessment of EPT’s
cost effectiveness.
At least one study thoroughly discussed a potential disadvantage of EPT. Because EPT is
provided as a sort of “end-point” in GC treatment (in other words, partners receive the EPT
medication and the “cascade” ends there). Clark, et al.’s (2017) study of partner notification in
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EPT therapy among MSM in Lima, Peru discusses what many consider a major shortcoming: the
potential to lose partners to valuable follow up care. The question is posed: if partners receive
EPT, are they then less likely to present for follow-up testing of HIV and Syphilis? This is an
especially pressing question given that STIs such as gonorrhea and chlamydia are known to
increase the risk of HIV transmission (Ward & Roenn, 2010).
The results of the study showed that significantly more EPT patients informed their
partners of their infection status than those advised through standard partner referral. 83% of
EPT patients informed their partners versus 58.3% for standard patient referral (95% confidence
intervals for both values included the named value and did not cross one, rendering them
statistically significant) (Clark, et al., 2017).
While the results of the study did show statistical significance for a key metric in EPT
(successful partner notification), the discussion of the potential for missed HIV/other STI
diagnoses and treatment was particularly poignant. This study called for future research into this
potential connection. The possibility of successful i ntervention for HIV was actually highlighted
as part of EPT, whereby EPT could be targeted to increase partner presentation for follow-up
(increased likelihood for follow up). This article correctly discussed how EPT may hold promise
for more than just the “short term bacterial STI cure…[but also] the indirect outcomes like HIV
and Syphilis.” (Clark, et al. 2017).
Results
Of the four RCTs reviewed which looked at EPT as an intervention, one large
population-based study showed no significant reduction in reinfection and further infection rates
among EPT patients (Golden, et al. 2015), one showed significant reduction (Kissinger, et al.,
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2005) and one showed a reduction in gonorrheal infection but not chlamydial infection (Golden,
et al., 2005). Additionally, the Cochrane meta-analysis performed by Ferreira, et al. (2013)
showed significant reduction in GC reinfection rates compared to standard partner notification,
however this meta-analysis used additional studies excluded from this literature review due to
age (prior to 2005) or were looking at trichomoniasis infections outside the purview of this
review.
Discussion
Although EPT does not employ first-line treatment, the body of current research includes
several RCTs which show decreases in recurrence and increased treatment uptake among
partners of GC cases. One large RCT did show statistical insignificance when looking at GC
re-infection rates (Golden, et al., 2015). However, such studies suffer from either decreased
relevance due to age (studies performed over a decade ago), lack of generalizability (focusing on
male only, or small men-who-have-sex-with-men populations), or statistical insignificance or
low power.
It appears that discussions of whether EPT remains the best practice for partner treatment
in GC infections centers on whether it has value as a harm reduction intervention. In other
words, second-line treatments such as oral cefixime are demonstrably inferior in treating GC
infection (Barbee, et al., 2018; Eyre, et al., 2017; Centers for Disease Control and Prevention,
2016; Kirkcaldy, et al., 2016). But should they be used when the alternative is potentially failing
to treat infected partners who cannot or will not present to providers? Are other methods such as
enhanced partner notification methods more effective than EPT? This literature review shows
that in the context of today’s antibiotic landscape, the answer is unclear. There have been no
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RCTs within the past five years that show EPT to be effective when using oral cefixime,
especially when there are now reports of rising ceftriaxone-resistant GC strains (Suay-Garcia and
Perez-Gracia, 2017).
Ancillary examination of EPT shows that there is only one readily available oral
alternative to Cefixime with comparable cure rates, the late-generation fluoroquinolone
Gemifloxacin. However, the most comprehensive evidence to date suggests that despite a high
cure rate (99.5%), adverse GI effects render it less desirable than Cefixime, especially with EPT
patients (Kirkcaldy, 2014). Such evidence further strengthens the argument that Cefixime-based
EPT remains the best available option to treat GC infections when partners are not available for
in-person treatment.
It should also be noted that this literature review brought up several interesting avenues
for potential further research. Evaluating the impact of intimate partner/domestic violence on
programs like EPT was discussed in one study and may be an important area in which EPT’s
lack of furthering harms could be shown (Unger, et al., 2015). Additionally, cost should be
viewed as an important metric for EPT’s viability. If EPT costs more than it benefits patients and
populations, then money might be better invested in other programs. One study (Gift, et al.,
2017) did show that this did not appear to be the case, and this strengthens the case for EPT.
Although these studies do seem to show EPT’s continued value for STI control, further
research is needed to address the shortcomings in the literature and to re-evaluate EPT in the
current circa-2018 antibiotic landscape. EPT is a form of harm reduction, and is a known use of
second-line treatment when no alternative appears better. Despite this, it nevertheless requires
the medical community to ensure it continues to be an evidence-based, recommended best
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practice. In the absence of viable alternatives, evidence showing EPT causes further harm, or
costs wildly outweighing potential benefits, EPT would appear to be the best available practice
for situations in which treating partners face-to-face is impossible or impractical.
Clinical Application
This review has relevance for clinicians practicing in many fields of medicine including
family practice, urgent care, emergency medicine, sexual health and STI clinics and public health
practice. Because EPT expressly directs providers to prescribe a treatment known to be inferior
(cefixime) to the first line treatment, evidence-based best practices are even more important.
Should the microbiological climate change to such an extent that cefixime were rendered
unusable against gonorrheal infections, EPT would clearly become impossible to justify.
Because that does not appear to be the case as of early 2019 in the United States, continued
research is justified and necessary to show that the cost, legislation, public health measures and
awareness campaigns surrounding EPT are still worthwhile.
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